Toh, Chee Keong

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,370

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing

Nahar, R., Zhai, W., Zhang, T., Takano, A., Khng, A. J., Lee, Y. Y., Liu, X., Lim, C. H., Koh, T. P. T., Aung, Z. W., et al. (2018) · Nature Communications

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 173

Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

Lai, G. G. Y., Lim, T. H., Lim, J., Liew, P. J. R., Kwang, X. L., Nahar, R., Aung, Z. W., Takano, A., Lee, Y. Y., Lau, D. P. X., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 118

Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Jain, A., Lim, C., Gan, E. M., Ng, D. Z., Ng, Q. S., Ang, M. K., Takano, A., Chan, K. S., Tan, W. M., Kanesvaran, R., et al. (2015) · PLOS ONE

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 32